13 August 2025

Solvonis Therapeutics plc

("Solvonis" or the "Company")

Media Coverage: Small Cap Idea profile in ThisIsMoney.co.uk / Daily Mail.

Solvonis Therapeutics plc (LSE: SVNS), a clinical-stage biopharmaceutical company developing novel medicines for addiction and mental health disorders, notes the publication of an article on ThisIsMoney.co.uk (Daily Mail online) titled "SMALL CAP IDEA: Ketamine drip therapy firm is taking on alcoholism".

The article, written by Ian Lyall of Proactive Investors, highlights:

· Solvonis' recent acquisition of Awakn Life Sciences and the integration of its development pipeline.

· The Company's lead programme, SVN-001, in Phase III clinical trials for severe AUD for the UK and EU AUD markets, combining ketamine infusion with Cognitive Behavioural Therapy (CBT).

· The Company's second programme, SVN-002, targeting the US AUD market via the FDA's 505(b)(2) regulatory pathway, referencing Johnson & Johnson's approved esketamine product Spravato®.

· Sector valuation comparisons with US-listed peers and recent M&A activity highlighting strategic interest in novel mental health therapeutics.

· The full article can be accessed here:
https://www.thisismoney.co.uk/money/markets/article-14996499/SMALL-CAP-IDEA-Ketamine-drip-therapy-firm-taking-alcoholism.html

Enquiries:

Solvonis Therapeutics plc
Anthony Tennyson, CEO & Executive Director
anthony@solvonis.com

Allenby Capital Limited (Financial Adviser and Joint Broker)
Nick Naylor / Nick Athanas / Ashur Joseph (Corporate Finance)
Guy McDougall (Sales & Corporate Broking)
+44 (0) 20 3328 5656

Singer Capital Markets (Joint Broker)
Phil Davies
+44 (0) 20 7496 3000

About Solvonis Therapeutics plc

Solvonis Therapeutics plc (LSE: SVNS) is a clinical-stage biopharmaceutical company developing novel medicines for addiction and mental health disorders. Headquartered in London and listed on the main market of the London Stock Exchange, Solvonis is advancing a differentiated pipeline of repurposed and novel compounds targeting high-burden neuropsychiatric conditions with significant unmet need.

The Company's lead programmes address Alcohol Use Disorder (AUD) and Post-Traumatic Stress Disorder (PTSD)-conditions affecting over 80 million people across the UK, US, and EU4. Its lead asset, SVN-001, is currently in Phase 3 for severe AUD in Europe and the UK. SVN-002 is preparing for a Phase 2b trial in the US targeting moderate to severe AUD. Solvonis also has a preclinical PTSD programme leveraging novel serotonin-dopamine modulators designed to enhance pro-social behaviour and long-term outcomes.

In addition, Solvonis is advancing an AI-supported discovery platform built on a proprietary CNS compound library, with initial focus on depression and stimulant use disorders. This initiative expands the Company's R&D pipeline into earlier-stage innovation while maintaining strategic focus on comorbid and underserved neuropsychiatric conditions.

With a capital-efficient model, dual development strategy, and near-term partnering opportunities, Solvonis is positioned to generate value through innovation in neuropsychiatry.

solvonis.com | LinkedIn | X (Twitter)